Research in Experimental Medicine

, Volume 193, Issue 1, pp 21–26 | Cite as

Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster

  • Bo Ahrén
  • Åke Andrén-Sandberg


Pancreatic cancer develops at approximately 25 weeks after 6 weeks of weekly subcutaneous administration of N-nitrosobis (2-oxypropyl)amine in the Syrian golden hamster. We studied the glucose tolerance and insulin secretion during the development of pancreatic cancer in this model. Every 6th week after start of treatment, glucose was infused intravenously for 30 min (10 mg/min). It was found that the glucose tolerance and glucose-stimulated insulin secretion were normal at 6, 12, and 18 weeks after start of treatment compared with agematched saline-injected controls. By contrast, after 24, 30, and 42 weeks an exaggerated plasma-glucose response and a concomitant impaired plasma-insulin response occurred during the glucose infusion (P<0.05). We therefore conclude that the development of pancreatic cancer in this model is accompanied by glucose intolerance and impaired insulin secretion, and that these effects occur concomitantly with the development of cancer.

Key words

Pancreatic cancer Nitrosamine Hamster Glucose tolerance Insulin secretion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ar'Rajab A, Ahreń B (1992) Long term diabetogenic effect of streptozotocin in rats. Pancreas (in press)Google Scholar
  2. 2.
    Berhowitz D, Greenberg L, Glassman S (1963) The intravenous tolbutamide test as a diagnostic aid in carcinoma of the pancreas. Am J Med Sci 243:150–154, 228–232Google Scholar
  3. 3.
    Braznin B, Steinberg JP, Leitner W, Sussman KE (1985) The nature of insulin secretory defect in aging rats. Diabetes 34:1168–1173CrossRefGoogle Scholar
  4. 4.
    Bruss ML, Black AL (1978) Enzymatic microdetermination of glycogen. Anal Biochem 84:309–312PubMedCrossRefGoogle Scholar
  5. 5.
    Cersosimo E, Pister PWT, Pesola G, McDermott K, Bajoninas D, Brennan MF (1991) Insulin secretion and action in patients with pancreatic cancer. Cancer 67:487–493CrossRefGoogle Scholar
  6. 6.
    Clark CG, Mitchell PEG (1961) Diabetes mellitus and primary carcinoma of the pancreas. BMJ 2:1259–1262PubMedCrossRefGoogle Scholar
  7. 7.
    Dawishiba S, Pour PM, Stenram U, Sundler F, Andrèn-Sandberg Å (1992) Immunohistochemical characterization of endocrine cells in experimental exocrine pancreatic cancer in the Syrian golden hamster. Int J Pancreatol (in press)Google Scholar
  8. 8.
    Eizirik DL, Sandler S (1989) Function and metabolism of pancreatic β-cells maintained in culture following experimentally induced damage. Pharmacol Toxicol 65:163–168PubMedGoogle Scholar
  9. 9.
    Herbert V, Lau KS, Gottlieb CW, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 26:1375–1384CrossRefGoogle Scholar
  10. 10.
    Murphy R, Smith FH (1963) Abnormal carbohydrate metabolism in pancreatic carcinoma. Med Clin North Am 47:397–405PubMedGoogle Scholar
  11. 11.
    Permert J, Mogahi M, Andrén-Sandberg Å, Kazahoff K, Pour PM (1992) Pancreatic mixed ductal-islet tumors. Is this an entitiy? Int J Pancreatol 11:23–29PubMedGoogle Scholar
  12. 12.
    Pour PM, Wilson RB (1990) Experimental tumors of the pancreas. In: Moosa AR (ed) Tumours of the pancreas. Williams & Wilkins, Baltimore London pp 37–158Google Scholar
  13. 13.
    Pour PM, Kruger FW, Althoff J, Cardesa A, Mohr U (1974) Cancer of the pancreas induced in the Syrian golden hamster. Am J Pathol 76:349–358PubMedGoogle Scholar
  14. 14.
    Schwartz SS, Zeidler A, Moossa AR, Kuku SF, Rubenstein A (1978) A prospective study of glucose tolerance, insulin, C-peptide and glucagon responses in patients with pancreatic carcinoma. Dig Dis Sci 23:1107–1114CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Bo Ahrén
    • 1
  • Åke Andrén-Sandberg
    • 1
  1. 1.Department of SurgeryLund UniversityLundSweden

Personalised recommendations